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Introduction {#sec1}
============

Obstructive sleep apnea (OSA) is a prevalent disease that significantly impacts quality of life. An apnea-hypopnea index (AHI) of 15 or greater increases risk for insulin resistance, dyslipidemia, vascular disease, and death[@bib1] While first line therapy for OSA is CPAP, long-term patient compliance is as low as 40%--60%.[@bib2], [@bib3] Studies also highlight a majority of patients do not use CPAP optimally.[@bib4] Low compliance and suboptimal use highlight the need for alternative therapies.

Surgical therapies for OSA are one alternative for those who fail CPAP. The impetus for these surgeries is to expand the airway by removing redundant tissue and prevent airway collapse at specific anatomic sites.[@bib1] Use of these methods remains controversial due to the lack of controlled studies assessing success, substantial side effects and the debate over measuring surgical success.[@bib5] These limitations highlight the need for a better secondary therapy.

One such therapy for those who have failed CPAP is direct stimulation of the hypoglossal nerve to increase pharyngeal muscle tone to prevent airway collapse.[@bib6] Several recent studies have examined the role of hypoglossal nerve stimulation (HNS) as a secondary therapy for OSA.[@bib7], [@bib8], [@bib9] HNS targets pharyngeal tone and stimulates genioglossus protrusion to maintain airway patency.[@bib6] These devices also reduce the risk for severe dysphagia and throat pain.[@bib10] Other key advantages include targeting airway collapse at multiple anatomic levels and the ability to titrate the device during sleep studies.[@bib10], [@bib11] Several recent clinical trials have looked at the efficacy of these devices.[@bib1], [@bib9], [@bib12], [@bib13] The purpose of this study was to perform a meta-analysis of available HNS studies to determine the role of HNS in treating OSA.

Methods {#sec2}
=======

A comprehensive literature search was performed with the assistance of a research librarian starting on August 14, 2017. Articles were identified in PubMed, Cochrane Database, and Scopus using search terms "obstructive sleep apnea and (implantable nerve stimulator or hypoglossal or Inspire implant or "STAR trial" or ImThera implant)" ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1PRISMA Diagram illustrating how studies were selected.Fig. 1

Selection criteria {#sec2.1}
------------------

Only studies with the primary objective of examining the role of hypoglossal nerve stimulation in treatment of sleep apnea in adults were included. Abstracts were independently reviewed by two reviewers (ARK and JSN), and case reports, review articles, and nonhuman studies were excluded. Full texts of included articles were reviewed for all clinical trials and case series. Articles without primary endpoints of Apnea Hypopnea Index (AHI), Oxygen Desaturation Index (ODI), and Epworth Sleepiness Scale (ESS) were excluded. Several studies also included Functional Outcomes of Sleep Questionnaire (FOSQ) and Sleep Apnea Quality of Life Index (SAQLI) and these outcomes were recorded. Adverse events from trials were also recorded for further analysis as well. Multiple studies included of the same cohort from the STAR trial. In an effort to only analyze this cohort once we used the largest cohort with the most complete follow up data available.

Statistical analysis {#sec2.2}
--------------------

The meta-analysis utilized pre-procedure (baseline) to post-procedure measures, with all subjects serving as their own controls. Meta-analysis of selected studies with a continuous measure (comparison of means and standard deviations between pre-procedure and post-procedure groups) was performed with Cochrane Review Manager (RevMan) version 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, 2011, Copenhagen, Denmark). Both the fixed effects model and the random effects model were used in this study. Under the fixed effects model, it is assumed that all studies come from a common population, and that the effect size (standardized mean difference) is not significantly different among the different trials. This assumption is tested by the "heterogeneity test." If this test yields a low probability value (*p* \< 0.05), then the fixed effects model may be invalid. In this case, the random effects model may be more appropriate, in which both the random variation within the studies and the variation between the different studies are incorporated. Under the random effects model, the true effects in the studies are assumed to vary between studies, and the summary effect is the weighted average of the effects reported in the different studies.[@bib14] The random effects model provides a more conservative estimate (i.e., with a wider confidence interval \[*CI*\]), but the results from the 2 models usually agree when there is no heterogeneity. When heterogeneity was present, the random effects model was the preferred model. Additionally, the Sterne and Egger tests were performed for further assessment of risk of publication bias.[@bib15], [@bib16] For this study, the null hypothesis was that there was no difference between pre-procedure and post-procedure with respect to AHI, ODI, ESS, and FOSQ. Data are presented as mean ± standard deviation (95% *CI*) in this text and as mean difference (MD) in the figures. The total MD with 95% *CI* is given for both the fixed effects model and the random effects model. If the value 0 is not inside the 95% *CI*, then the MD is statistically significant at the 5% level (*p* \< 0.05).

In addition, a meta-analysis of proportions was done for surgical outcomes. The program MedCalc 17.9.7 (MedCalcSoftware, Oostende, Belgium) lists the proportions (expressed as a percentage), with their 95% *CI*s, found in the individual studies included in the meta-analysis. The pooled proportion with 95% *CI* is given both for the fixed effects model and the random effects model. Each technique was weighted according to the number of patients treated. Analysis of pooled proportions was performed where appropriate. MedCalc used a Freeman-Tukey transformation to calculate the weighted summary proportion under the fixed and random effects models.[@bib17], [@bib18] Data were presented as weighted proportions with corresponding 95% *CI*s. Both the fixed effects model and the random effects model were used in this study.

Results {#sec3}
=======

Through a comprehensive literature review 16 papers were identified for the systematic review.[@bib1], [@bib8], [@bib9], [@bib12], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] Meta-analysis of 12 studies encompassing 381 patients was also performed. According to the Oxford Centre for Evidence-Based Medicine grading system, the methodological quality of the studies was assessed as level of evidence 4, since they were case series. Sterne and Egger testing suggested a relationship between the sample size of these studies and their effect sizes indicating a high likelihood of publication bias. These data were significantly heterogeneous (*I*^2^ = 64%, *p* \< 0.00001).

Objective and subjective outcomes of HNS {#sec3.1}
----------------------------------------

At 6 months, mean AHI was reduced by 23.5 (*p* \< 0.00001, 95%*CI*, 19.4--27.6) and mean ODI was reduced by 13.4 (*p* \< 0.00001, 95%*CI*, 11.0 to 15.8) ([Fig. 2](#fig2){ref-type="fig"}). At 6 months, mean ESS was reduced by 5.0 (95%*CI*, 4.1--5.8), mean FOSQ improved by 3.1 (*p* \< 0.00001, 95%*CI*, 2.6--3.8), and mean SAQLI improved by 3.1 (*p* = 0.008, 95%*CI*, 2.6--3.8) ([Fig. 3](#fig3){ref-type="fig"}). At 12 months, mean AHI was reduced by 21.1 (*p* \< 0.00001, 95%*CI*, 16.9--25.2) and mean ODI was reduced by 15.0 (*p* \< 0.00001, 95%*CI*, 13.3--16.7) ([Fig. 4](#fig4){ref-type="fig"}). At 12 months, mean ESS remained reduced by 4.8 (*p* \< 0.00001, 95%*CI,* 4.2--5.4) and mean FOSQ improved by 3.1 (*p* \< 0.00001, 95%*CI*, 2.6--3.7) ([Fig. 5](#fig5){ref-type="fig"}).Fig. 2Objective outcomes are significantly improved at 6 months as demonstrated by AHI and ODI. **A:** AHI Baseline vs. 6 month and AHI is significantly decreased over baseline. **B**: ODI Baseline vs. 6 months and ODI is significantly decreased over baseline.Fig. 2Fig. 3Subjective outcomes are significantly improved from baseline to 6 months. **A:** ESS Baseline vs. 6 months shows significant improvement at 6 months. **B**: FOSQ Baseline vs. 6 months shows significant improvement. **C**: SAQLI Baseline vs. 6 months.Fig. 3Fig. 4Objective outcomes remain improved at 12 months as measured by AHI and ODI. **A**: AHI Baseline vs. 12 months and AHI is significantly decreased over baseline. **B**: ODI Baseline vs. 12 months and ODI is significantly decreased over baseline.Fig. 4Fig. 5Patient reported subjective outcomes remain improved over baseline at 12 months. **A**: ESS Baseline vs. 12 months shows significant improvement at 12 months. **B**: FOSQ Baseline vs. 12months shows significant improvement at 12 months.Fig. 5

### Safety of HNS {#sec3.1.1}

Several adverse events ([Table 1](#tbl1){ref-type="table"}) were relatively common among patients. 6.2% of patients experienced pain (*p* \< 0.0001, 95%*CI*, 0.7%--16.%). 11.0% of patients had a tongue abrasion with or without lesions (*p* \< 0.0001, 95%*CI*. 1.2%--28.7%). 3.0% of patients experienced an internal device malfunction (*p* = 0.0001, 95%*CI*, 0.3%--8.4%) and 5.8% of patients experienced an external device malfunction (*p* \< 0.0001, 95%*CI*, 0.3%--17.4%). 7.0% of patients experienced some other adverse event (*p* \< 0.0001, 95%*CI*, 0.6%--19.2%).Table 1Safety of Hypoglossal Nerve Stimulation.Table 1ItemsPercent of patients95% *CIp*-valuePain6.2%0.7%--16.6%*p* \< 0.0001Tongue abrasion11.0%1.2%--28.7%*p* \< 0.0001Internal device malfunction3.0%0.3%--8.4%*p* = 0.0001External device malfunction5.8%0.3%--17.4%*p* \< 0.0001Other7.0%0.6%--19.2%*p* \< 0.0001

Discussion {#sec4}
==========

OSA imposes significant cardiovascular risk and daytime sleepiness increases risk of automobile accidents.[@bib30], [@bib31] CPAP is currently the first line therapy, but alternative therapies, such as HNS, are necessary due to the improper use of and poor compliance with CPAP. This meta-analysis and systematic review examined 16 clinical trials that reported objective and subjective outcomes for CPAP refractory OSA treated with HNS to understand its clinical utility. Across all trials, patients that receive HNS have significantly improved AHI, ODI, and FOSQ at 6 and 12 months ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}).

While HNS may not be the definitive choice for second line therapy, it is a useful tool in managing OSA. Through several case series, a cohort of patients that would benefit most from HNS has been defined: patients with a BMI less than \<35 kg/m^2^, an AHI between 20 and 50, and nonconcentric collapse of the retropalatal airway.[@bib1], [@bib28], [@bib32] Difficulties with compliance with CPAP may warrant HNS use as compliance was reported to be 86% at 12 months compared to 40%--60% with CPAP.[@bib1], [@bib2], [@bib3], [@bib29] Interestingly, one study found that discontinuation of HNS did not immediately cause patients to revert to baseline AHI or ODI.[@bib22] This response highlights the potential for HNS to modify the disease course of OSA. However, long-term discontinuation results in reversion to baseline characteristics.[@bib33]

Common adverse events across all studies included pain, tongue abrasion and device malfunction ([Table 1](#tbl1){ref-type="table"}). Pain, which was managed with analgesics, was characterized as a non-serious adverse event by most trials. However, one trial noted 3 patients with serious pain, which resolved for only 1 patient.[@bib19] Tongue abrasions were a common and expected side effect for HNS, as the device stimulates the genioglossus to protrude the tongue against teeth.[@bib1] These abrasions were remedied by reprogramming the device or using a tooth guard.[@bib1] Other adverse events mentioned by authors included abnormal sensations, paresthesias, change in salivary flow and lip weakness.[@bib1], [@bib7], [@bib9], [@bib12], [@bib19], [@bib21], [@bib26], [@bib27], [@bib28] A serious complication in previous studies was device migration, and further study to prevent this complication may be necessary. Of note, there was no mention of dysphagia in any trial, a common complaint in traditional upper airway surgeries.

One key limitation is the lack of long-term follow-up data for implanted patients. While most trials focused on time points within 1 year following implantation, the authors of the STAR trial have published follow up data for 18, 24, 36, and 48 months. They demonstrated the device maintains effectiveness.[@bib25], [@bib27], [@bib29], [@bib34] A meta-analysis on the role of HNS on sleep outcomes was performed previously.[@bib35] However, our study performs further analysis of risks via a meta-analysis of proportions. Furthermore, several studies have been published since this that previous systematic review, including a large multi-institution post market study.[@bib7], [@bib19], [@bib20], [@bib26], [@bib27], [@bib29]

Further investigation is needed to compare traditional airway surgery to HNS. Currently, there is a shortage of evidence of what role traditional airway surgery plays compared to HNS. However, one case report presented a patient with an extensive history of unsuccessful upper airway surgery who underwent HNS improved drastically improved.[@bib36] Several trials included in our analysis mentioned patients in their cohorts that had previous surgeries, but no study has further investigated how this cohort faired compared to those without previous upper airway surgery.[@bib13], [@bib33]

Conclusions {#sec5}
===========

HNS is a safe and effective treatment for CPAP refractory OSA. HNS is associated with high compliance and significantly improves subjective and objective outcomes of sleep. Complications are generally uncommon and benign. Further study comparing HNS to other therapies, such as airway surgery, is required.
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